1Saltz LB, Meropol N J, Loehrer PJ Sr, et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor [ J ]. J Clin Oncol, 2004,22 : 1201-1208.
2Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004,351:337-345.
4Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase Ⅱ and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines[ J]. J Clin Oncol, 2006,24:4914-4921.
5Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor ( EGFR ) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies [J]. J Clin Oncol, 2004,22:4772-4778.
6Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [ J ]. J Clin Oncol, 2005,23 : 1803-1810.
7Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [ J ]. Cancer Res, 2006,66:3992-3995.
8Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor ( EGFR ) and clinical response to antiEGFR treatment in coloreetal cancer: a cohort study [ J ]. Lancet Oncol, 2005,6:279-286.
9Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab [ J ]. J Clin Oncol, 2007,25:3712-3718.
10Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy[ J]. J Clin Oncol, 2007,25:3930-3935.
2Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and eetuximab plus irinoteean in irinoteean - refractory metastatic eolorectal eaneer[J]. N Engl J Med, 2004, 351:337 -345.
3Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor[J]. Clincancer res, 2001,7:2958-2970.
4Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004, 351:337-345.
5Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy [J]. J Clin Oncol, 2005, 23: 3536-3544.
6Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study[J]. Lancet Oncol, 2005, 6:279-286.
7Cutsem E V. Progress with biological agents in metastatic colorectal cancer leads to many challenges[J]. J Clin Oncol, 2006,24:3325-3327.
8Delbaldo C, Pierga JY, Dieras V, et al. Pharmacokinetic profile of cetuximab (Erbitux^TM) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma[J].Eur J Cancer, 2005,41: 1739-1745.
